Reportlinker Adds Colorectal Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Q4 2010
NEW YORK, Oct. 12 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Colorectal Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Q4 2010
Colorectal Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Q4 2010
Summary
GlobalData, the industry analysis specialist, has released its new report, "Colorectal Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Q4 2010". The report is an essential source of information and analysis on the global colorectal cancer therapeutics market. The report provides comprehensive information on colorectal cancer, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the global colorectal cancer therapeutics market. It analyses the treatment usage patterns in the global colorectal cancer therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global colorectal cancer sector. It quantifies the unmet need in the global colorectal cancer therapeutics market as well as in the individual markets such as the US and the top five countries in Europe, highlighting the opportunity for future players.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Scope
The Scope of the report includes:
- An overview of colorectal cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized global colorectal cancer therapeutics market revenue, annual cost of therapy and treatment usage patterns data from 2001 to 2009, forecast for 11 years to 2020.
- Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France Japan and BRIC countries that include Brazil, Russia, India and China
- Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events.
- Competitor assessment including drug launch analysis and drug sales forecasts.
- Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, LCM activities, product positioning and drug sales forecast.
- Analysis of unmet need in the market and target product profile including opportunity for target product.
- Technology trends analytic framework to assess strength of pipeline.
- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include EGFR inhibitors, VEGF inhibitors, monoclonal antibodies, angiogenesis inhibitors and others.
- An overview of the most promising drugs' including clinical study details, efficacy, safety, collaboration agreements, marketing rights, and launch analysis and drug sales forecasts to 2020.
- Analysis of the current and future market competition in the US Colorectal Cancer therapeutics market. Company profiles including business description, financial overview and SWOT analysis. Key future market players covered include Hoffmann-La Roche Ltd, Bristol-Myers Squibb, Eli Lilly, Sanofi-Aventis, Debiopharm Group and Merck KGaA.
- Analysis of licensing agreements during 2004-2010 in the colorectal cancer therapeutics market. M&A analysis which includes M&A deals by size and geography.
- Strategic assessment of the market through market impact analysis, future market scenario and company analysis.
- Direct quotes from key opinion leaders (KOL) or physicians in the colorectal cancer therapeutics market in the US.
Reasons to buy
The report will enhance your decision making capability. It will allow you to:
- Develop business strategies and perform superior market quantification analysis by
- Understanding the trends shaping and driving the global colorectal cancer therapeutics market.
- Understanding treatment preferences of physicians in disease state and across treatment flow.
- Accessing market sizing, forecasts and quantified growth opportunities in the global colorectal cancer therapeutics market till 2020.
- Quantifying patient population in the global colorectal cancer market to better design product pricing & launch plans.
- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by
- Performing benchmarking analysis and growth opportunities against currently marketed products
- Identifying market entry points based on safety, efficacy, and pricing parameters.
- Assessing competitiveness of products in market by understanding the strength and weakness of current competition.
- Develop and design your in-licensing and out-licensing strategies by
- Taking a comprehensive look of at the disease pipeline and identifying most promising paradigm shifting products.
- Assessing strength of pipeline bases on first in class, me-too, generic and lifecycle management of products.
- Track drug sales in the global colorectal cancer therapeutics market from 2001 to 2020
- Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
- What's the next big thing in the global colorectal cancer therapeutics market landscape? Identify, understand and capitalize.
1 Colorectal Cancer: Executive Summary
1.1 The Global Colorectal Cancer Therapeutics Market was Worth $7.0 billion in 2009, Driven by the Growth in the Patient Volume and Annual Cost of Colorectal Cancer Therapy
1.2 The Current Competition in the Global Colorectal Cancer Therapeutics Market is Weak as None of the Drugs Completely Addressed the Unmet Needs
1.3 The Colorectal Cancer Pipeline is Strong with Many Novel First-in-class Molecules in Late-stage Clinical Development
1.4 High Unmet Needs Exist in the Colorectal Cancer Therapeutics Market in terms of Efficacy and Safety
2 Disease Overview
2.1 Overview
2.2 Epidemiology
2.3 Etiology
2.4 Symptoms
2.4.1 Colon Cancer
2.4.2 Rectal Cancer
2.5 Diagnosis
2.5.1 FOBT
2.5.2 Endoscopy
2.5.3 Optical Colonoscopy
2.5.4 Virtual Colonoscopy
2.5.5 Double Contrast Barium Enema (DCBE)
2.6 Pathology
2.6.1 Grading
2.7 Treatment
2.7.1 Colon Cancer Treatment by Stage
2.7.2 Rectal Cancer Treatment by Stage
2.7.3 Chemotherapy Options
2.8 Treatment Guidelines
3 Market Characterization
3.1 Global
3.1.1 Market Size
3.1.2 Drivers and Barriers
3.1.3 Forecasts
3.1.4 Drug Sales
3.2 The US
3.2.1 Market Size
3.2.2 Drivers and Barriers
3.2.3 Forecasts
3.2.4 Drug Sales
3.2.5 Pricing and Reimbursements
3.3 The UK
3.3.1 Market Size
3.3.2 Drivers and Barriers
3.3.3 Impact on the Market
3.3.4 Forecasts
3.3.5 Drug Sales
3.3.6 Pricing and Reimbursements
3.4 Germany
3.4.1 Market Size
3.4.2 Drivers and Barriers
3.4.3 Impact on the Market
3.4.4 Forecasts
3.4.5 Drug Sales
3.4.6 Pricing and Reimbursements
3.5 France
3.5.1 Market Size
3.5.2 Drivers and Barriers
3.5.3 Impact on the Market
3.5.4 Forecasts
3.5.5 Drug Sales
3.5.6 Pricing & Reimbursements
3.6 Italy
3.6.1 Market Size
3.6.2 Drivers and Barriers
3.6.3 Impact on the Market
3.6.4 Forecasts
3.6.5 Drug Sales
3.6.6 Pricing and Reimbursements
3.7 Spain
3.7.1 Market Size
3.7.2 Drivers and Barriers
3.7.3 Impact on the Market
3.7.4 Forecasts
3.7.5 Drug Sales
3.7.6 Pricing and Reimbursements
3.8 Japan
3.8.1 Market Size
3.8.2 Drivers and Barriers
3.8.3 Impact on the Market
3.8.4 Forecasts
3.8.5 Future Impact
3.8.6 Drug Sales
3.8.7 Pricing and Reimbursements
3.9 Brazil
3.9.1 Market Size
3.9.2 Drivers and Restraints
3.9.3 Impact on the Market
3.9.4 Forecasts
3.9.5 Future Impact
3.10 India
3.10.1 Market Size
3.10.2 Drivers and Restraints
3.10.3 Impact on the Market
3.10.4 Forecasts
3.10.5 Future Impact
3.11 China
3.11.1 Market Size
3.11.2 Drivers and Restraints
3.11.3 Impact on the Market
3.11.4 Forecasts
3.11.5 Future Impact
3.12 Russia
3.12.1 Market Size
3.12.2 Drivers and Restraints
3.12.3 Impact on the Market
3.12.4 Forecasts
3.12.5 Future Impact
3.13 Key Takeaway
4 Competitor Assessment
4.1 Strategic Competitor Assessment
4.1.1 Overview
4.1.2 Benchmarking
4.1.3 Current Competitor Assessment
4.2 Launch Analysis and Sales Forecasts
4.2.1 Market Share Analysis of Drugs
4.3 Product Profiles
4.3.1 Avastin (bevacizumab)
4.3.2 Erbitux (cetuximab)
4.3.3 Xeloda (capecitabine)
4.3.4 Vectibix (panitumumab)
4.3.5 Eloxatin (oxaliplatin)
4.3.6 Camptosar (irinotecan)
4.3.7 Fluorouracil (5-FU)
4.3.8 Leucovorin (folinic acid)
4.4 Key Takeaway
5 Pipeline Assessment
5.1 Overview
5.2 Pipeline Analysis by Phase of Development
5.3 Pipeline by Mechanism of Action
5.4 Strategic Pipeline Assessment
5.4.1 Technology Trends Analytical Framework
5.5 Trends in Colorectal Cancer Pipeline
5.5.1 Increase in the Number of Vaccines in R&D Targeted at Stage III Colorectal Cancer
5.5.2 Novel First-in-Class Molecules in Late-stage Clinical Development Strengthening the Pipeline
5.5.3 Failure of key Molecules in Phase II and Phase III Development
5.6 Partners in Development
5.6.1 Licensing Agreements by Phase of Development
5.6.2 Licensing Agreements by Geography
5.6.3 Licensing Agreements: Colorectal Cancer Screening / Diagnostic Technology
5.7 Most Promising Drugs' Profiles
5.7.1 Aflibercept
5.7.2 Brivanib
5.7.3 OncoVAX
5.7.4 TroVax
5.7.5 KRX-0401 (Perifosine)
5.8 Colorectal Cancer Pipeline – Preclinical Phase
5.9 Colorectal Cancer Pipeline – Phase I
5.10 Colorectal Cancer Pipeline – Phase II
5.11 Colorectal Cancer Pipeline – Phase III
5.12 Key Takeaway
5.13 Unmet Need
5.14 Opportunity for Target Product
5.15 Target Product Profile
5.15.1 Ideal Characteristics
5.15.2 Target Product Description
5.16 Key Takeaway
6 Strategic Assessment
6.1 Key Events Impacting the Future Market
6.2 Market Impact Analysis
6.3 Future Market Scenario
6.4 Company Analysis
6.4.1 Market Leadership
6.4.2 Future Players in the Market
6.5 Key Takeaway
7 Company Profiles
7.1 F. Hoffmann La Roche
7.1.1 Business Description
7.1.2 Financial Overview
7.1.3 SWOT Analysis
7.2 Bristol-Myers Squibb
7.2.1 Business Description
7.2.2 Financial Overview
7.2.3 SWOT Analysis
7.3 Sanofi-Aventis
7.3.1 Business Description
7.3.2 Financial Overview
7.3.3 SWOT Analysis
7.4 Debiopharm Group
7.4.1 Business Description
7.5 Merck KGaA
7.5.1 Business Description
7.5.2 Financial Overview
7.5.3 SWOT Analysis
7.6 Regeneron
7.6.1 Business Description
7.6.2 Financial Overview
7.6.3 SWOT Analysis
7.7 Vaccinogen BD
7.7.1 Overview
7.7.2 SWOT Analysis
7.8 Oxford BioMedica
7.8.1 Business Description
7.8.2 Financial Overview
7.8.3 SWOT Analysis
7.9 Auron Healthcare GmbH
7.9.1 Company Overview
7.10 AEterna Zentaris
7.10.1 Business Description
7.10.2 Financial Overview
7.10.3 SWOT Analysis
7.11 Keryx
7.11.1 Business Description
7.11.2 Financial Overview
7.11.3 SWOT Analysis
7.12 Abbott Laboratories
7.12.1 Business Description
7.12.2 Financial Performance
7.12.3 SWOT Analysis
7.13 Pfizer
7.13.1 Business Description
7.13.2 Financial Overview
7.13.3 SWOT Analysis
7.14 Light Sciences Oncology, Inc
7.14.1 Business Description
7.14.2 Financial Overview
7.14.3 SWOT Analysis
8 Deals Analysis
8.1 Key Highlights
8.2 Key Deals' Analysis
8.2.1 Eli Lilly Acquires ImClone
8.2.2 Astellas Pharma Acquires OSI Pharmaceuticals
8.2.3 Takeda Acquires IDM Pharma
8.2.4 Alchemia Acquires Meditech
8.2.5 Sanofi-Aventis Acquired Additional 15% Stake in Regeneron
8.2.6 BBM Holdings to Acquire YM Biosciences
8.2.7 Pfizer Acquires Assets of Campto from Sanofi-Aventis
8.2.8 Peptech Acquires cancer Antibodies from Scancell
8.2.9 Quest Pharma Tech Inc. Acquired Late Stage Immunotherapy Product Pipeline of Paladin Labs
8.2.10 Spectrum Pharmaceuticals Inc Acquired Oncology Drug Assets from Targent Inc
8.3 Deals Analysis by Geography
8.4 Deals Analysis by Deal Size
9 Expert Opinion
9.1 US
9.2 UK
9.3 Germany
9.4 Italy
9.5 Spain
9.6 Japan
10 Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Research Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
Analogous Forecasting Methodology
Diseased Population
Treatment Seeking Population
Diagnosis Population
Prescription Population
Forecasting Model for Therapeutic Areas
10.3.4 Primary Research
10.3.5 Expert Panel validation
10.3.6 Contact Us
10.3.7 Disclaimer
10.3.8 SourcesTable 1: Colorectal Cancer Therapeutics Market, Global, Staging of Colorectal Cancer, 2010
Table 2: Colorectal Cancer Therapeutics Market, Global, WHO Classification of Colorectal Carcinomas, 2010
Table 3: Colorectal Cancer Therapeutics Market, Global, Sales Value ($bn), 2001–2009
Table 4: Colorectal Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2001–2009
Table 5: Colorectal Cancer Therapeutics Market, Global, Patient Volume ('000), 2001–2009
Table 6: Colorectal Cancer Therapeutics Market, Global, Treatment Usage Patterns, 2001–2009
Table 7: Colorectal Cancer Therapeutics Market, Global, Sales Value ($bn), 2009–2020
Table 8: Colorectal Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2009–2020
Table 9: Colorectal Cancer Therapeutics Market, Global, Patient Volume ('000), 2009–2020
Table 10: Colorectal Cancer Therapeutics Market, Global, Treatment Usage Patterns (millions), 2009–2020
Table 11: Colorectal Cancer Therapeutics Market, Global, Drug Sales ($m), 2001-2010
Table 12: Colorectal Cancer Therapeutics Market, Global, Drug Sales ($m), 2010-2020
Table 13: Colorectal Cancer Therapeutics Market, The US, Sales Value ($bn), 2001–2009
Table 14: Colorectal Cancer Therapeutics Market, The US, Annual Cost of Therapy ($), 2001–2009
Table 15: Colorectal Cancer Therapeutics Market, The US, Patient Volume (1000's), 2001–2009
Table 16: Colorectal Cancer Therapeutics Market, The US, Treatment Usage Patterns, 2001–2009
Table 17: Colorectal Cancer Therapeutics Market, The US, Sales Value ($bn), 2009–2020
Table 18: Colorectal Cancer Therapeutics Market, The US, Sales Value ($bn), 2009–2020
Table 19: Colorectal Cancer Therapeutics Market, The US, Patient Volume ('000), 2009–2020
Table 20: Colorectal Cancer Therapeutics Market, The US, Treatment Usage Patterns (millions), 2009–2020
Table 21: Colorectal Cancer, The US, Drug Sales ($m), 2001-2010
Table 22: Colorectal Cancer, The US, Drug Sales ($m), 2011-2020
Table 23: Colorectal Cancer Therapeutics Market, The UK, Sales Value ($bn), 2001–2009
Table 24: Colorectal Cancer Therapeutics Market, The UK, Annual Cost of Therapy ($), 2001–2009
Table 25: Colorectal Cancer Therapeutics Market, The UK, Patient Volume ('000), 2001–2009
Table 26: Colorectal Cancer Therapeutics Market, The UK, Treatment Usage Patterns, 2001–2009
Table 27: Colorectal Cancer, The UK, Sales Value ($bn), 2009–2020
Table 28: Colorectal Cancer Therapeutics Market, The UK, Annual Cost of Therapy ($), 2009–2020
Table 29: Colorectal Cancer Therapeutics Market, The UK, Patient Volume, 2009–2020
Table 30: Colorectal Cancer Therapeutics Market, The UK, Treatment Usage Patterns ('000), 2009–2020
Table 31: Colorectal Cancer Therapeutics Market, The UK, Drug Sales ($m), 2001-2020
Table 32: Colorectal Cancer Therapeutics Market, The UK, Drug Sales ($m), 2001-2020
Table 33: Colorectal Cancer Therapeutics Market, Germany, Sales Value ($bn), 2001–2009
Table 34: Colorectal Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2001–2009
Table 35: Colorectal Cancer Therapeutics Market, Germany, Patient Volume ('000), 2001–2009
Table 36: Colorectal Cancer Therapeutics Market, Germany, Treatment Usage Patterns, 2001–2009
Table 37: Colorectal Cancer Therapeutics Market, Germany, Sales Value ($bn), 2009–2020
Table 38: Colorectal Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2009–2020
Table 39: Colorectal Cancer Therapeutics Market, Germany, Patient Volume ('000), 2009–2020
Table 40: Colorectal Cancer Therapeutics Market, Germany, Treatment Usage Patterns, 2009–2020
Table 41: Colorectal Cancer Therapeutics Market, Germany, Drug Sales ($m), 2001-2010
Table 42: Colorectal Cancer Therapeutics Market, Germany, Drug Sales ($m), 2011-2020
Table 43: Colorectal Cancer Therapeutics Market, France, Sales Value ($), 2001–2009
Table 44: Colorectal Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2001–2009
Table 45: Colorectal Cancer Therapeutics Market, France, Patient Volume ('000), 2001–2009
Table 46: Colorectal Cancer Therapeutics Market, France, Treatment Usage Patterns, 2001–2009
Table 47: Colorectal Cancer Therapeutics Market, France, Sales Value ($bn), 2009–2020
Table 48: Colorectal Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2009–2020
Table 49: Colorectal Cancer Therapeutics Market, France, Patient Volume ('000), 2009–2020
Table 50: Colorectal Cancer Therapeutics Market, France, Treatment Usage Patterns, 2009–2020
Table 51: Colorectal Cancer Therapeutics Market, France, Drug Sales ($m), 2001-2010
Table 52: Colorectal Cancer Therapeutics Market, France, Drug Sales ($m), 2011-2020
Table 53: Colorectal Cancer Therapeutics Market, Italy, Sales Value ($bn), 2001–2009
Table 54: Colorectal Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2001–2009
Table 55: Colorectal Cancer Therapeutics Market, Italy, Patient Volume ('000), 2001–2009
Table 56: Colorectal Cancer Therapeutics Market, Italy, Treatment Usage Patterns, 2001–2009
Table 57: Colorectal Cancer Therapeutics Market, Italy, Sales Value ($bn), 2009–2020
Table 58: Colorectal Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2009–2020
Table 59: Colorectal Cancer Therapeutics Market, Italy, Patient Volume, 2009–2020
Table 60: Colorectal Cancer Therapeutics Market, Italy, Treatment Usage Patterns, 2009–2020
Table 61: Colorectal Cancer Therapeutics Market, Italy, Drug Sales ($m), 2001-2010
Table 62: Colorectal Cancer Therapeutics Market, Italy, Drug Sales ($m), 2011-2020
Table 63: Colorectal Cancer Therapeutics Market, Spain, Sales Value ($bn), 2001–2009
Table 64: Colorectal Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2001–2009
Table 65: Colorectal Cancer Therapeutics Market, Spain, Patient Volume (1000's), 2001–2009
Table 66: Colorectal Cancer Therapeutics Market, Spain, Treatment Usage Patterns, 2001–2009
Table 67: Colorectal Cancer Therapeutics Market, Spain, Sales Value ($bn), 2009–2020
Table 68: Colorectal Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2009–2020
Table 69: Colorectal Cancer Therapeutics Market, Spain, Patient Volume ('000), 2009–2020
Table 70: Colorectal Cancer Therapeutics Market, Spain, Treatment Usage Patterns, 2009–2020
Table 71: Colorectal Cancer Therapeutics Market, Spain, Drug Sales ($m), 2001-2010
Table 72: Colorectal Cancer Therapeutics Market, Spain, Drug Sales ($m), 2011-2020
Table 73: Colorectal Cancer Therapeutics Market, Japan, Sales Value ($bn), 2001–2009
Table 74: Colorectal Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2001–2009
Table 75: Colorectal Cancer Therapeutics Market, Japan, Patient Volume ('000), 2001–2009
Table 76: Colorectal Cancer Therapeutics Market, Japan, Treatment Usage Patterns, 2001–2009
Table 77: Colorectal Cancer Therapeutics Market, Japan, Sales Value ($bn), 2009–2020
Table 78: Colorectal Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2009–2020
Table 79: Colorectal Cancer Therapeutics Market, Japan, Patient Volume ('000), 2009–2020
Table 80: Colorectal Cancer Therapeutics Market, Japan, Treatment Usage Patterns, 2009–2020
Table 81: Colorectal Cancer Therapeutics Market, Japan, Drug Sales ($m), 2001-2020
Table 82: Colorectal Cancer Therapeutics Market, Japan, Drug Sales ($m), 2001-2020
Table 83: Colorectal Cancer Therapeutics Market, Brazil, Sales Value ($m), 2001–2009
Table 84: Colorectal Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2001–2009
Table 85: Colorectal Cancer Therapeutics Market, Brazil, Patient Volume, 2001–2009
Table 86: Colorectal Cancer Therapeutics Market, Brazil, Treatment Usage Patterns, 2001–2009
Table 87: Colorectal Cancer Therapeutics Market, Brazil, Sales Value ($m), 2009–2020
Table 88: Colorectal Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2009–2020
Table 89: Colorectal Cancer Therapeutics Market, Brazil, Patient Volume, 2009–2020
Table 90: Colorectal Cancer Therapeutics Market, Brazil, Treatment Usage Patterns, 2009–2020
Table 91: Colorectal Cancer Therapeutics Market, India, Sales Value ($m), 2001–2009
Table 92: Colorectal Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2001–2009
Table 93: Colorectal Cancer Therapeutics Market, India, Patient Volume, 2001–2009
Table 94: Colorectal Cancer Therapeutics Market, India, Treatment Usage Patterns, 2001–2009
Table 95: Colorectal Cancer Therapeutics Market, India, Sales Value ($m), 2009–2020
Table 96: Colorectal Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2009–2020
Table 97: Colorectal Cancer Therapeutics Market, India, Patient Volume, 2009–2020
Table 98: Colorectal Cancer Therapeutics Market, India, Treatment Usage Patterns, 2009–2020
Table 99: Colorectal Cancer Therapeutics Market, China, Sales Value ($m), 2001–2009
Table 100: Colorectal Cancer Therapeutics Market, China, Annual Cost of Therapy ($), 2001–2009
Table 101: Colorectal Cancer Therapeutics Market, China, Patient Volume, 2001–2009
Table 102: Colorectal Cancer Therapeutics Market, China, Treatment Usage Patterns, 2001–2009
Table 103: Colorectal Cancer Therapeutics Market, China, Sales Value ($m), 2009–2020
Table 104: Colorectal Cancer Therapeutics Market, China, Annual Cost of Therapy ($), 2009–2020
Table 105: Colorectal Cancer Therapeutics Market, China, Patient Volume, 2009–2020
Table 106: Colorectal Cancer Therapeutics Market, China, Treatment Usage Patterns, 2009–2020
Table 107: Colorectal Cancer Therapeutics Market, Russia, Sales Value ($m), 2001–2009
Table 108: Colorectal Cancer Therapeutics Market, Russia, Annual Cost of Therapy ($), 2001–2009
Table 109: Colorectal Cancer Therapeutics Market, Russia, Patient Volume, 2001–2009
Table 110: Colorectal Cancer Therapeutics Market, Russia, Treatment Usage Patterns, 2001–2009
Table 111: Colorectal Cancer Therapeutics Market, Russia, Sales Value ($m), 2009–2020
Table 112: Colorectal Cancer Therapeutics Market, Russia, Annual Cost of Therapy ($), 2009–2020
Table 113: Colorectal Cancer Therapeutics Market, Russia, Patient Volume, 2009–2020
Table 114: Colorectal Cancer Therapeutics Market, Russia, Treatment Usage Patterns, 2009–2020
Table 115: Colorectal Cancer, Global, Safety Profile of Standard Treatment, 2010
Table 116: Colorectal Cancer Therapeutics Market, Global, Benchmarking Major Marketed Products, 2010
Table 117: Colorectal Cancer, Global, Avastin Adverse Effects Incidence, 2010
Table 118: Colorectal Cancer Therapeutics Market, Global, Erbitux, Incidence of Adverse Effects, 2010
Table 119: Colorectal Cancer Therapeutics Market, Global, Xeloda, Adverse Effects Incidence, 2010
Table 120: Colorectal Cancer Therapeutics Market, Global, Vectibix, PRECEPT Interim Results, 2010
Table 121: Colorectal Cancer Therapeutics Market, Global, Vectibix, Incidence of Adverse Events, 2010
Table 122: Colorectal Cancer Therapeutics Market, Global, Eloxatin, Efficacy, 2010
Table 123: Colorectal Cancer Therapeutics Market, Global, Eloxatin, Incidence of Adverse Events, 2010
Table 124: Colorectal Cancer Therapeutics Market, Global, Technology Licensing Agreements Description, 2010
Table 125: Colorectal Cancer Therapeutics Market, Global, Preclinical Phase Pipeline, July 2010
Table 126: Colorectal Cancer, Global, Phase I Pipeline, July 2010
Table 127: Colorectal Cancer, Global, Phase II Pipeline, July 2010
Table 128: Colorectal Cancer, Global, Phase III Pipeline, July 2010
Table 129: Colorectal Cancer Therapeutics Market, Global, Commonly Prescribed Treatment Options, 2010
Table 130: Colorectal Cancer Therapeutics Market, Global, Characteristics of Ideal Drug Which Satisfies the Unmet Needs, 2010
Table 131: Colorectal Cancer Therapeutics Market, Global, Description of Ideal Drug Which Satisfies the Unmet Needs, 2010
Figure 1: Colorectal Cancer Therapeutics Market, Global, Sales Value ($bn), 2001-2020
Figure 2: Colorectal Cancer Therapeutics Market, Global, Pipeline by Mechanism of Action, 2010
Figure 3: Colorectal Cancer Therapeutics Market, Global, Opportunity and Unmet Need, 2009
Figure 4: Colorectal Cancer, Global, Colon Cancer Treatment Guidelines, 2010
Figure 5: Colorectal Cancer, Global, Rectal Cancer Treatment Guidelines, 2010
Figure 6: Colorectal Cancer Therapeutics Market, Global, Sales Value ($bn), 2001–2009
Figure 7: Colorectal Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2001–2009
Figure 8: Colorectal Cancer Therapeutics Market, Global, Patient Volume, 2001–2009
Figure 9: Colorectal Cancer Therapeutics Market, Global, Treatment Usage Patterns, 2001–2009
Figure 10: Colorectal Cancer Therapeutics Market, Global, Market Drivers and Restraints, 2009
Figure 11: Colorectal Cancer Therapeutics Market, Global, The Impact of Historical Events on the Market, 2010
Figure 12: Colorectal Cancer Therapeutics Market, Global, Sales Value ($bn), 2009–2020
Figure 13: Colorectal Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2009–2020
Figure 14: Colorectal Cancer Therapeutics Market, Global, Patient Volume (absolute), 2009–2020
Figure 15: Colorectal Cancer Therapeutics Market, Global, Treatment Usage Patterns, 2009–2020
Figure 16: Colorectal Cancer Therapeutics Market, Global, Future Market Drivers and Restraints, 2009–2020
Figure 17: Colorectal Cancer Therapeutics Market, Global, Drug Sales ($m), 2001-2020
Figure 18: Colorectal Cancer Therapeutics Market, Global, Market Breakdown by Drug Sales (%), 2009
Figure 19: Colorectal Cancer Therapeutics Market, The US, Sales Value ($bn), 2001–2009
Figure 20: Colorectal Cancer Therapeutics Market, The US, Annual Cost of Therapy ($), 2001–2009
Figure 21: Colorectal Cancer Therapeutics Market, The US, Patient Volume (absolute), 2001–2009
Figure 22: Colorectal Cancer Therapeutics Market, The US, Treatment Usage Patterns, 2001–2009
Figure 23: Colorectal Cancer Therapeutics Market, The US, Market Drivers and Restraints, 2009
Figure 24: Colorectal Cancer Therapeutics Market, The US, The Impact of Historical Events on the Market, 2010
Figure 25: Colorectal Cancer Therapeutics Market, The US, Sales Value ($bn), 2009–2020
Figure 26: Colorectal Cancer Therapeutics Market, The US, Annual Cost of Therapy ($), 2009–2020
Figure 27: Colorectal Cancer Therapeutics Market, The US, Patient Volume (absolute), 2009–2020
Figure 28: Colorectal Cancer Therapeutics Market, The US, Treatment Usage Patterns, 2009–2020
Figure 29: Colorectal Cancer Therapeutics Market, The US, Future Market Drivers and Restraints, 2009–2020
Figure 30: Colorectal Cancer, The US, Drug Sales ($m), 2001-2020
Figure 31: Colorectal Cancer Therapeutics Market, The UK, Sales Value ($bn), 2001–2009
Figure 32: Colorectal Cancer Therapeutics Market, The UK, Annual Cost of Therapy ($), 2001–2009
Figure 33: Colorectal Cancer Therapeutics Market, The UK, Patient Volume (absolute), 2001–2009
Figure 34: Colorectal Cancer Therapeutics Market, The UK, Treatment Usage Patterns, 2001–2009
Figure 35: Colorectal Cancer Therapeutics Market, The UK, Market Drivers and Restraints, 2009
Figure 36: Colorectal Cancer Therapeutics Market, The UK, The Impact of Historical Events on the Market, 2010
Figure 37: Colorectal Cancer Therapeutics Market, The UK, Sales Value ($bn), 2009–2020
Figure 38: Colorectal Cancer, The UK, Annual Cost of Therapy ($), 2009–2020
Figure 39: Colorectal Cancer Therapeutics Market, The UK, Patient Volume, 2009–2020
Figure 40: Colorectal Cancer Therapeutics Market, The UK, Treatment Usage Patterns, 2009–2020
Figure 41: Colorectal Cancer Therapeutics Market, The UK, Future Market Drivers and Restraints, 2009–2020
Figure 42: Colorectal Cancer Therapeutics Market, The UK, Drug Sales ($m), 2001-2020
Figure 43: Colorectal Cancer Therapeutics Market, Germany, Sales Value ($bn), 2001–2009
Figure 44: Colorectal Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2001–2009
Figure 45: Colorectal Cancer Therapeutics Market, Germany, Patient Volume, 2001–2009
Figure 46: Colorectal Cancer Therapeutics Market, Germany, Treatment Usage Patterns, 2001–2009
Figure 47: Colorectal Cancer Therapeutics Market, Germany, Market Drivers and Restraints, 2009
Figure 48: Colorectal Cancer Therapeutics Market, Germany, The Impact of Historical Events on the Market, 2010
Figure 49: Colorectal Cancer Therapeutics Market, Germany, Sales Value ($bn), 2009–2020
Figure 50: Colorectal Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2009–2020
Figure 51: Colorectal Cancer Therapeutics Market, Germany, Patient Volume, 2009–2020
Figure 52: Colorectal Cancer Therapeutics Market, Germany, Treatment Usage Patterns, 2009–2020
Figure 53: Colorectal Cancer Therapeutics Market, Germany, Future Market Drivers and Restraints, 2009–2020
Figure 54: Colorectal Cancer Therapeutics Market, Germany, Drug Sales ($m), 2001-2020
Figure 55: Colorectal Cancer Therapeutics Market, France, Sales Value ($bn), 2001–2009
Figure 56: Colorectal Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2001–2009
Figure 57: Colorectal Cancer Therapeutics Market, France, Patient Volume, 2001–2009
Figure 58: Colorectal Cancer Therapeutics Market, France, Treatment Usage Patterns, 2001–2009
Figure 59: Colorectal Cancer Therapeutics Market, France, Market Drivers and Restraints, 2009
Figure 60: Colorectal Cancer Therapeutics Market, France, The Impact of Historical Events on the Market, 2010
Figure 61: Colorectal Cancer Therapeutics Market, France, Sales Value ($bn), 2009–2020
Figure 62: Colorectal Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2009–2020
Figure 63: Colorectal Cancer Therapeutics Market, France, Patient Volume, 2009–2020
Figure 64: Colorectal Cancer Therapeutics Market, France, Treatment Usage Patterns, 2009–2020
Figure 65: Colorectal Cancer Therapeutics Market, France, Future Market Drivers and Restraints, 2009–2020
Figure 66: Colorectal Cancer Therapeutics Market, France, Drug Sales ($m), 2001-2020
Figure 67: Colorectal Cancer Therapeutics Market, Italy, Sales Value ($bn), 2001–2009
Figure 68: Colorectal Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2001–2009
Figure 69: Colorectal Cancer Therapeutics Market, Italy, Patient Volume, 2001–2009
Figure 70: Colorectal Cancer Therapeutics Market, Italy, Treatment Usage Patterns, 2001–2009
Figure 71: Colorectal Cancer Therapeutics Market, Italy, Market Drivers and Restraints, 2009
Figure 72: Colorectal Cancer Therapeutics Market, Italy, The Impact of Historical Events on the Market, 2010
Figure 73: Colorectal Cancer Therapeutics Market, Italy, Sales Value ($bn), 2009–2020
Figure 74: Colorectal Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2009–2020
Figure 75: Colorectal Cancer Therapeutics Market, Italy, Patient Volume, 2009–2020
Figure 76: Colorectal Cancer Therapeutics Market, Italy, Treatment Usage Patterns, 2009–2020
Figure 77: Colorectal Cancer Therapeutics Market, Italy, Future Market Drivers and Restraints, 2009–2020
Figure 78: Colorectal Cancer Therapeutics Market, Italy, Drug Sales ($m), 2001-2020
Figure 79: Colorectal Cancer Therapeutics Market, Spain, Sales Value ($bn), 2001–2009
Figure 80: Colorectal Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2001–2009
Figure 81: Colorectal Cancer Therapeutics Market, Spain, Patient Volume, 2001–2009
Figure 82: Colorectal Cancer Therapeutics Market, Spain, Treatment Usage Patterns, 2001–2009
Figure 83: Colorectal Cancer Therapeutics Market, Spain, Market Drivers and Restraints, 2009
Figure 84: Colorectal Cancer Therapeutics Market, Spain, The Impact of Historical Events on the Market, 2010
Figure 85: Colorectal Cancer Therapeutics Market, Spain, Sales Value ($bn), 2009–2020
Figure 86: Colorectal Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2009–2020
Figure 87: Colorectal Cancer Therapeutics Market, Spain, Patient Volume, 2009–2020
Figure 88: Colorectal Cancer Therapeutics Market, Spain, Treatment Usage Patterns, 2009–2020
Figure 89: Colorectal Cancer Therapeutics Market, Spain, Future Market Drivers and Restraints, 2009–2020
Figure 90: Colorectal Cancer Therapeutics Market, Spain, Drug Sales ($m), 2001-2020
Figure 91: Colorectal Cancer Therapeutics Market, Japan, Sales Value ($bn), 2001–2009
Figure 92: Colorectal Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2001–2009
Figure 93: Colorectal Cancer Therapeutics Market, Japan, Patient Volume, 2001–2009
Figure 94: Colorectal Cancer Therapeutics Market, Japan, Treatment Usage Patterns, 2001–2009
Figure 95: Colorectal Cancer Therapeutics Market, Japan, Market Drivers and Restraints, 2009
Figure 96: Colorectal Cancer Therapeutics Market, Japan, The Impact of Historical Events on the Market, 2010
Figure 97: Colorectal Cancer Therapeutics Market, Japan, Sales Value ($bn), 2009–2020
Figure 98: Colorectal Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2009–2020
Figure 99: Colorectal Cancer Therapeutics Market, Japan, Patient Volume, 2009–2020
Figure 100: Colorectal Cancer Therapeutics Market, Japan, Treatment Usage Patterns, 2009–2020
Figure 101: Colorectal Cancer Therapeutics Market, Japan, Future Events Expected to Impact the Market, 2010
Figure 102: Colorectal Cancer Therapeutics Market, Japan, Drug Sales ($m), 2001-2020
Figure 103: Colorectal Cancer Therapeutics Market, Brazil, Sales Value ($m), 2001–2009
Figure 104: Colorectal Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2001–2009
Figure 105: Colorectal Cancer Therapeutics Market, Brazil, Patient Volume, 2001–2009
Figure 106: Colorectal Cancer Therapeutics Market, Brazil, Treatment Usage Patterns, 2001–2009
Figure 107: Colorectal Cancer Therapeutics Market, Brazil, Market Drivers and Restraints, 2009
Figure 108: Colorectal Cancer Therapeutics Market, Brazil, The Impact of Historical Events on the Market, 2010
Figure 109: Colorectal Cancer Therapeutics Market, Brazil, Sales Value ($m), 2009–2020
Figure 110: Colorectal Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2009–2020
Figure 111: Colorectal Cancer Therapeutics Market, Brazil, Patient Volume, 2009–2020
Figure 112: Colorectal Cancer Therapeutics Market, Brazil, Treatment Usage Patterns, 2009–2020
Figure 113: Colorectal Cancer Therapeutics Market, Brazil, Future Market Drivers and Restraints, 2009–2020
Figure 114: Colorectal Cancer Therapeutics Market, India, Sales Value ($m), 2001–2009
Figure 115: Colorectal Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2001–2009
Figure 116: Colorectal Cancer Therapeutics Market, India, Patient Volume, 2001–2009
Figure 117: Colorectal Cancer Therapeutics Market, India, Treatment Usage Patterns, 2001–2009
Figure 118: Colorectal Cancer Therapeutics Market, India, Market Drivers and Restraints, 2009
Figure 119: Colorectal Cancer Therapeutics Market, India, The Impact of Historical Events on the Market, 2010
Figure 120: Colorectal Cancer Therapeutics Market, India, Sales Value ($m), 2009–2020
Figure 121: Colorectal Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2009–2020
Figure 122: Colorectal Cancer Therapeutics Market, India, Patient Volume, 2009–2020
Figure 123: Colorectal Cancer Therapeutics Market, India, Treatment Usage Patterns, 2009–2020
Figure 124: Colorectal Cancer Therapeutics Market, India, Future Market Drivers and Restraints, 2009–2020
Figure 125: Colorectal Cancer Therapeutics Market, China, Sales Value ($m), 2001–2009
Figure 126: Colorectal Cancer Therapeutics Market, China, Annual Cost of Therapy ($), 2001–2009
Figure 127: Colorectal Cancer Therapeutics Market, China, Patient Volume, 2001–2009
Figure 128: Colorectal Cancer Therapeutics Market, China, Treatment Usage Patterns, 2001–2009
Figure 129: Colorectal Cancer Therapeutics Market, China, Market Drivers and Restraints, 2010
Figure 130: Colorectal Cancer Therapeutics Market, China, The Impact of Historical Events on the Market, 2010
Figure 131: Colorectal Cancer Therapeutics Market, China, Sales Value ($m), 2009–2020
Figure 132: Colorectal Cancer Therapeutics Market, China, Annual Cost of Therapy ($), 2009–2020
Figure 133: Colorectal Cancer Therapeutics Market, China, Patient Volume, 2009–2020
Figure 134: Colorectal Cancer Therapeutics Market, China, Treatment Usage Patterns, 2009–2020
Figure 135: Colorectal Cancer Therapeutics Market, China, Future Market Drivers and Restraints, 2009–2020
Figure 136: Colorectal Cancer Therapeutics Market, Russia, Sales Value ($m), 2001–2009
Figure 137: Colorectal Cancer Therapeutics Market, Russia, Annual Cost of Therapy ($), 2001–2009
Figure 138: Colorectal Cancer Therapeutics Market, Russia, Patient Volume, 2001–2009
Figure 139: Colorectal Cancer Therapeutics Market, Russia, Treatment Usage Patterns, 2001–2009
Figure 140: Colorectal Cancer Therapeutics Market, Russia, Market Drivers and Restraints, 2009
Figure 141: Colorectal Cancer Therapeutics Market, Russia, The Impact of Historical Events on the Market, 2010
Figure 142: Colorectal Cancer Therapeutics Market, Russia, Sales Value ($m), 2009–2020
Figure 143: Colorectal Cancer Therapeutics Market, Russia, Annual Cost of Therapy ($), 2009–2020
Figure 144: Colorectal Cancer Therapeutics Market, Russia, Patient Volume, 2009–2020
Figure 145: Colorectal Cancer Therapeutics Market, Russia, Treatment Usage Patterns, 2009–2020
Figure 146: Colorectal Cancer Therapeutics Market, Russia, Future Market Drivers and Restraints, 2009–2020
Figure 147: Colorectal Cancer Therapeutics Market, Global, Clinical Endpoints for Benchmarking, 2010
Figure 148: Colorectal Cancer Therapeutics Market, Global, Strategic Competitor Assessment of Major Marketed Drugs, 2010
Figure 149: Colorectal Cancer Therapeutics Market, Global, Sales Forecast Split by Therapies, 2001-2020
Figure 150: Colorectal Cancer Therapeutics Market, Global, Avastin, Life Cycle Management Activities, 2004–2010
Figure 151: Colorectal Cancer Therapeutics Market, Global, Avastin, Sales Forecast ($m), 2004-2020
To order this report:
Drug and Medication Industry: Colorectal Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Q4 2010
Drug and Medication Business News
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg |
|
Reportlinker |
|
Email: [email protected] |
|
US: (805)652-2626 |
|
Intl: +1 805-652-2626 |
|
SOURCE Reportlinker
Share this article